journal article·2022-12-21Open access

Phosphorylcholine-Based Contact Lenses for Sustained Release of Resveratrol: Design, Antioxidant and Antimicrobial Performances, and In Vivo Behavior

Maria Vivero-Lopez, Ana F. Pereira-da-Mota, Gonzalo Carracedo, Fernando Huete-Toral, Ana Parga, Ana Otero, Angel Concheiro, Carmen Alvarez-Lorenzo

ACS Applied Materials & Interfaces· Volume 14· Issue 50

Abstract

Design of advanced contact lenses (CLs) demands materials that are safe and comfortable for the wearers and that preserve the normal eye microbiota, avoiding chronic inflammation and biofilm development. This work aimed to combine the natural antibiofouling phosphorylcholine and the antioxidant and prebiotic resveratrol as integral components of CLs that may have the additional performance of preventing oxidative-stress related eye diseases. Different from previous uses of 2-methacryloyloxyethyl phosphorylcholine (MPC) as coating, we explored the feasibility of adding MPC at high proportions as a comonomer of 2-hydroxyethyl methacrylate (HEMA)-based hydrogels while still allowing for the loading of the hydrophobic resveratrol. Homogeneous distribution of MPC along the hydrogel depth (confirmed by Raman spectroscopy) notably increased solvent uptake and the proportion of free water while it decreased Young's modulus. Relevantly, MPC did not hinder the uptake of resveratrol by CLs (>10 mg/g), which indeed showed network/water partition coefficients of >100. Protocols for CLs sterilization and loading of resveratrol under aseptic conditions were implemented, and the effects of tear proteins on resveratrol release rate were investigated. CLs sustained resveratrol release for more than 24 h in vitro, and sorption of albumin onto the hydrogel, although attenuated by MPC, slowed down the release. The combination of MPC and resveratrol reduced P. aeruginosa and S. aureus growth as tested in a novel hydrogel disk-agar interface biofilm growth setup. The developed CLs showed excellent anti-inflammatory properties and biocompatibility in in ovo and rabbit tests and provided higher and more prolonged levels of resveratrol in tear fluid, which favored resveratrol biodistribution in anterior and posterior eye segments compared to eye drops. Correlations between the release profiles of resveratrol in vitro and in vivo were assessed. Relevantly, the CLs preserved the antioxidant properties of resveratrol during the entire 8 h of wearing. In sum, CLs prepared with high proportion in MPC may help address safety and comfort requirements while having drug releasing capabilities.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Glaucoma and retinal disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782Santiago de Compostela, Spain

Ocupharm Research Group, Faculty of Optics and Optometry, Complutense University of Madrid, C/Arcos del Jalon 118, 28037Madrid, Spain

Department of Optometry and Vision, Faculty of Optics and Optometry, Complutense University of Madrid, C/Arcos del Jalon 118, 28037Madrid, Spain

Departamento de Microbiología y Parasitología, Facultad de Biología, Edificio CIBUS, Universidade de Santiago de Compostela, 15782Santiago de Compostela, Spain

Funding

Ministerio de Ciencia e Innovaci?n · European Regional Development Fund · H2020 Marie Sklodowska-Curie Actions · Xunta de Galicia

References (70)

Show source-provided references
1. 10.1016/j.clae.2021.02.00710.1016/j.clae.2021.02.007 ↗
2. 10.1167/tvst.10.14.510.1167/tvst.10.14.5 ↗
3. 10.1016/j.jconrel.2022.02.01410.1016/j.jconrel.2022.02.014 ↗
4. 10.1002/aisy.20200026310.1002/aisy.202000263 ↗
5. 10.5582/bst.2019.0117810.5582/bst.2019.01178 ↗
6. 10.2174/138920372066619082015250810.2174/1389203720666190820152508 ↗
7. 10.1016/j.preteyeres.2019.10080410.1016/j.preteyeres.2019.100804 ↗
8. 10.1016/j.actbio.2020.06.03910.1016/j.actbio.2020.06.039 ↗
9. 10.3390/pathogens401011110.3390/pathogens4010111 ↗
10. 10.1128/mBio.00198-1610.1128/mBio.00198-16 ↗
11. 10.1021/acs.langmuir.0c0279610.1021/acs.langmuir.0c02796 ↗
12. 10.1016/j.actbio.2021.04.01410.1016/j.actbio.2021.04.014 ↗
13. 10.1021/acsami.0c0214310.1021/acsami.0c02143 ↗
14. 10.1016/j.ijpharm.2018.10.04110.1016/j.ijpharm.2018.10.041 ↗
15. 10.1016/j.actbio.2018.11.02010.1016/j.actbio.2018.11.020 ↗
16. 10.1021/acsami.1c2220510.1021/acsami.1c22205 ↗
17. 10.1002/admi.20190142210.1002/admi.201901422 ↗
18. 10.1021/acsomega.0c0632710.1021/acsomega.0c06327 ↗
19. 10.1116/6.000036610.1116/6.0000366 ↗
20. 10.1016/j.surfcoat.2018.03.07810.1016/j.surfcoat.2018.03.078 ↗
21. 10.1038/nbt.231610.1038/nbt.2316 ↗
22. 10.1586/17434440.3.2.16710.1586/17434440.3.2.167 ↗
23. Liu, Y.Polymerizable Contact Lens Formulations and Contact Lenses Obtained Therefrom. U.S. Patent US8011784B2, September 6, 2011.
24. 10.3390/pharmaceutics1304053210.3390/pharmaceutics13040532 ↗
25. 10.1039/C9BM01582E10.1039/C9BM01582E ↗
26. 10.1167/iovs.14-1570810.1167/iovs.14-15708 ↗
27. 10.3390/microorganisms807103310.3390/microorganisms8071033 ↗
28. 10.1038/srep0546710.1038/srep05467 ↗
29. 10.1016/j.ijantimicag.2018.03.00210.1016/j.ijantimicag.2018.03.002 ↗
30. 10.3390/ijms2211551410.3390/ijms22115514 ↗
31. 10.3390/ijms2203129510.3390/ijms22031295 ↗
32. 10.1080/03639045.2020.182890910.1080/03639045.2020.1828909 ↗
33. 10.1016/j.jddst.2021.10278710.1016/j.jddst.2021.102787 ↗
34. 10.1016/j.saa.2017.01.01310.1016/j.saa.2017.01.013 ↗
35. 10.1002/jps.2076110.1002/jps.20761 ↗
36. 10.1016/j.clae.2004.08.00310.1016/j.clae.2004.08.003 ↗
37. 10.1016/j.msec.2019.11009210.1016/j.msec.2019.110092 ↗
38. 10.14227/DT180311P1510.14227/DT180311P15 ↗
39. ICCVAM. ICCVAM Test Method Evaluation Report: Current Validation Status of In Vitro Test Methods Proposed for Identifying Eye Injury Hazard Potential of Chemicals and Products. NIH Publication No. 10-7553; National Institute of Environmental Health Sciences: Research Triangle Park, NC, U.S., 2010; p 1324.
40. 10.1016/j.msec.2020.11160610.1016/j.msec.2020.111606 ↗
41. 10.1016/j.ijpharm.2022.12228110.1016/j.ijpharm.2022.122281 ↗
42. Whittaker A. L. · J. Am. Assoc. Lab. Anim. Sci. · 2015 · 54 · 783
43. 10.1016/j.jconrel.2019.05.02510.1016/j.jconrel.2019.05.025 ↗
44. 10.1002/jbm.a.3663510.1002/jbm.a.36635 ↗
45. 10.1097/OPX.000000000000164210.1097/OPX.0000000000001642 ↗
46. 10.3390/ma1304094310.3390/ma13040943 ↗
47. 10.1016/j.colsurfb.2020.11153910.1016/j.colsurfb.2020.111539 ↗
48. 10.1016/j.molstruc.2004.10.11810.1016/j.molstruc.2004.10.118 ↗
49. 10.1016/j.polymer.2004.11.01610.1016/j.polymer.2004.11.016 ↗
50. Yeung K. K. · Rev. Optom. · 2018 · 155 · 30
51. 10.1016/j.ejpb.2015.04.00210.1016/j.ejpb.2015.04.002 ↗
52. 10.1002/pat.94810.1002/pat.948 ↗
53. 10.3390/ijms1603578910.3390/ijms16035789 ↗
54. 10.1021/jf101206710.1021/jf1012067 ↗
55. Lorentz H. · Mol. Vision · 2011 · 17 · 3392
56. 10.1167/tvst.5.6.310.1167/tvst.5.6.3 ↗
57. 10.1016/j.biomaterials.2005.06.01010.1016/j.biomaterials.2005.06.010 ↗
58. 10.1163/156856294X0041910.1163/156856294X00419 ↗
59. 10.1016/j.biomaterials.2009.06.00510.1016/j.biomaterials.2009.06.005 ↗
60. 10.1007/978-1-61779-080-5_2010.1007/978-1-61779-080-5_20 ↗
61. 10.3390/molecules2601022910.3390/molecules26010229 ↗
62. 10.1021/acsami.0c0762910.1021/acsami.0c07629 ↗
63. 10.2174/187152731566615111012495710.2174/1871527315666151110124957 ↗
64. 10.1016/j.jconrel.2017.01.01210.1016/j.jconrel.2017.01.012 ↗
65. 10.1089/jop.2019.010910.1089/jop.2019.0109 ↗
66. 10.3109/02713683.2015.105073810.3109/02713683.2015.1050738 ↗
67. 10.1016/j.ijpharm.2017.03.08310.1016/j.ijpharm.2017.03.083 ↗
68. 10.1016/j.jconrel.2022.06.00110.1016/j.jconrel.2022.06.001 ↗
69. 10.1016/j.ifset.2009.07.00210.1016/j.ifset.2009.07.002 ↗
70. 10.1016/j.ijpharm.2018.04.00410.1016/j.ijpharm.2018.04.004 ↗